Eliquis Faces Major Revenue Decline Due to Patent Expiry
Eliquis, a top-selling anticoagulant developed by Bristol Myers Squibb and Pfizer, is expected to face a significant revenue decline due to patent expiries in Europe in 2026 and the US and Japan in 2027. Global sales are projected to drop from $14.4 billion in 2025 to $205 million in 2031, representing a 98.6% decline.
Topics: Bristol_Myers_Squibb Eliquis generic_competition Pfizer pharmaceutical_patents revenue_forecast